Dereje Abate Negatu

Dr. Dereje Abate Negatu

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 April 2019 in mBio
Verified
Journal Article
Open access
PDF file
DNDereje Abate Negatu
Dereje Abate Negatu
YYYoshiyuki Yamada
Yoshiyuki Yamada
YXYu Xi
Yu Xi
MGMei Lin Go
Mei Lin Go
MZMatthew Zimmerman
Matthew Zimmerman
Thomas DickThomas Dick
Thomas Dick
New drugs against tuberculosis are urgently needed. The tryptophan (Trp) analog indole propionic acid (IPA) is the first antitubercular metabolite produced by human gut bacteria. Here, we show that this antibiotic blocks Trp synthesis, an in vivo essential biosynthetic pathway in M. tuberculosis . Intriguingly, IPA acts by decoupling a bacterial feedback regulatory mechanism: it mimics Trp as allosteric inhibitor of anthranilate synthase, thereby switching off Trp synthesis regardless of intracellular Trp levels. The identification of IPA’s target paves the way for the discovery of more potent TrpE ligands employing rational, target-based lead optimization.

1 March 2018 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
DNDereje Abate Negatu
Dereje Abate Negatu
JLJoe J. J. Liu
Joe J. J. Liu
MZMatthew Zimmerman
Matthew Zimmerman
FKFirat Kaya
Firat Kaya
VDVéronique Dartois
Véronique Dartois
Thomas DickThomas Dick
Thomas Dick
Several key antituberculosis drugs, including pyrazinamide, with a molecular mass of 123.1 g/mol, are smaller than the usual drug-like molecules. Current drug discovery efforts focus on the screening of larger compounds with molecular masses centered around 400 to 500 g/mol. Fragment (molecular mass < 300 g/mol) libraries have not been systematically explored for antitubercular activity. Here we screened a collection of 1,000 fragments, present in the Maybridge Ro3 library, for whole-cell activity against Mycobacterium tuberculosis . Twenty-nine primary hits showed dose-dependent growth inhibition equal to or better than that of pyrazinamide. The most potent hit, indole propionic acid [IPA; 3-(1 H -indol-3-yl)propanoic acid], a metabolite produced by the gut microbiota, was profiled in vivo . The molecule was well tolerated in mice and showed adequate pharmacokinetic properties. In a mouse model of acute M. tuberculosis infection, IPA reduced the bacterial load in the spleen 7-fold. Our results suggest that IPA should be evaluated as an add-on to current regimens and that fragment libraries should be further explored to identify antimycobacterial lead candidates.

28 August 2012 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
DNDereje Abate Negatu
Dereje Abate Negatu
BTBineyam Taye
Bineyam Taye
MAMohammed Abseno
Mohammed Abseno
SBSibhatu Biadgilign
Sibhatu Biadgilign
Background: Drug-resistant TB has emerged as a major challenge facing TB prevention and control efforts. In Ethiopia, the extent/trend of drug resistance TB is not well known. The aim of this study was to determine the pattern and trend of resistance to first line anti-TB drugs among culture positive retreatment cases at St.Peter’s TB Specialized Hospital. Findings: A hospital based retrospective study was used to assess the pattern of anti-TB drug resistance among previously treated TB patients referred to St.Peter’s TB Specialized Hospital from January 2004-December 2008 Gregorian calendar(GC) for better diagnosis and treatment. Among 376 culture positive for M. tuberculosis one hundred and two (27.1%) were susceptible to all of the four first line anti-TB drugs -Isoniazid (INH), Rifampicin (RIF), Ethambutol (ETB) & Streptomycin (STM). While 274 (72.9%) were resistant to at least one drug. Any resistance to STM (67.3%) was found to be the most common and the prevalence of MDR-TB was 174 (46.3%). Trend in resistance rate among re-treatment cases from 2004 to 2008 showed a significant increase for any drug as well as for INH, RIF, and MDR resistance (P <0.05 for trend). Conclusions: There has been an increasing trend in drug resistance in recent years, particularly in retreatment cases. Therefore, establishing advanced diagnostic facilities for early detection of MDR-TB and expanding second line treatment center to treat MDR-TB patients and to prevent its transmission is recommended.

18 April 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
DNDereje Abate Negatu
Dereje Abate Negatu
WAWassihun Wedajo Aragaw
Wassihun Wedajo Aragaw
JCJulianna Cangialosi
Julianna Cangialosi
VDVeronique A Dartois
Veronique A Dartois
Thomas DickThomas Dick
Thomas Dick
New oxazolidinones are in clinical development for the treatment of tuberculosis and nontuberculous mycobacterial (NTM) infections, as a replacement for linezolid and tedizolid, which cause mitochondrial toxicity after prolonged treatment. Here, we carried out side-by-side measurements of mitochondrial protein synthesis inhibition and activity against clinically relevant mycobacterial pathogens of approved and novel oxazolidinones.

1 August 2014 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
DNDereje Abate Negatu
Dereje Abate Negatu
YTY. Tedla
Y. Tedla
DMD. Meressa
D. Meressa
GAGobena Ameni
Gobena Ameni
St Peter's TB Specialized Hospital, Addis Ababa, Ethiopia. To estimate the prevalence of mutations that cause resistance to isoniazid (INH) and rifampicin (RMP) and assess the effects of these mutations on second-line anti-tuberculosis treatment. GenoType(®)MTBDRplus assay results and clinical data documented at St Peter's TB Specialized Hospital over 3 years were retrospectively collected and analysed. The results indicated that 68.7% (n = 470) of RMP-resistant isolates had mutations at codon 531 (S531L) of the rpoB gene, while 93% (n = 481) of the INH-resistant isolates had mutations at codon 315 (S315T1) of the katG gene. The proportion of inhA mutations was 0.8% (n = 481). Treatment outcome was unfavourable in 23.7% (n = 76) of patients treated with second-line anti-tuberculosis drugs. Mutations in other codons of the rpoB gene (P > 0.05) and in the inhA promoter region (P > 0.05) were not associated with unfavourable treatment outcomes. The predominant mutations in RMP and INH resistance were observed at codons 531 and 315 in the rpoB and katG genes, respectively. Mutations in the inhA region were rare, which shows its minimal contribution to the development of resistance to ethionamide. This also suggests that treating multidrug-resistant TB patients with high doses of INH may have little effect.

16 February 2023 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
DNDereje Abate Negatu
Dereje Abate Negatu
RRRubén González del Río
Rubén González del Río
MCMónica Cacho-Izquierdo
Mónica Cacho-Izquierdo
DBDavid Barros-Aguirre
David Barros-Aguirre
JLJoël Lelievre
Joël Lelievre
Thomas DickThomas Dick
Thomas Dick
The combination of the β-lactam tebipenem and the β-lactamase inhibitor avibactam shows potent bactericidal activity against Mycobacterium abscessus in vitro . Here, we report that the combination of the respective oral prodrugs tebipenem-pivoxil and avibactam ARX-1796 showed efficacy in a mouse model of M. abscessus lung infection.